Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Antiviral Therapy

• Publication date

  2015-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3851/IMP2821PMID 25105742PMCID PMC4320979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy

  2013cited by this paper
• The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank

  2013cited by this paper
• No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.

  2013cited by this paper
• Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients

  2013cited by this paper
• Epidemiology and natural history of HCV infection

  2013cited by this paper
• Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

  2013cited by this paper
• Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d’Ivoire

  2013cited by this paper
• Hepatitis C Virus Adaptation to T-Cell Immune Pressure

  2013cited by this paper
• Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

  2013cited by this paper
• Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

  2013cited by this paper
• Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.

  2013cited by this paper
• Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing

  2012cited by this paper
• Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.

  2012cited by this paper
• Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing

  2012cited by this paper
• Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy

  2012cited by this paper
• Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor

  2012cited by this paper
• Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.

  2012cited by this paper
• Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir

  2012cited by this paper
• Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.

  2012cited by this paper
• Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

  2012cited by this paper
• Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

  2011cited by this paper
• Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing

  2011cited by this paper
• Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals

  2011cited by this paper
• Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.

  2011cited by this paper
• Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.

  2011cited by this paper
• Treatment of acute HCV infection

  2011cited by this paper
• 67 MOLECULAR CHARACTERIZATION OF HCV RESISTANCE TO TELAPREVIR BY MEANS OF ULTRA-DEEP PYROSEQUENCING: PREEXISTING RESISTANT VARIANTS AND DYNAMICS OF RESISTANT POPULATIONS

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.

  2010cited by this paper
• Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

  2010cited by this paper
• Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)

  2009cited by this paper
• Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.

  2009cited by this paper
• Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy

  2009cited by this paper
• Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance

  2009cited by this paper
• Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen–restricted immune pressure

  2009cited by this paper
• Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo

  2009cited by this paper
• Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment‐naïve chronically infected patient

  2008cited by this paper
• Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

  2008cited by this paper
• Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

  2008influential reference
• Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• Interactive Selective Pressures of Hla-Restricted Immune Responses and Antiretroviral Drugs on HIV-1

  2005cited by this paper
• American Association for the Study of Liver Diseases

  1959cited by this paper

• Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

  2022cites this paper
• The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting

  2021cites this paper
• Infection and Drug Resistance Dovepress

  2019cites this paper
• Pre-treatment Antiviral Resistance in Australians with Chronic Hepatitis C: Prevalence of NS3 and NS5A Resistance Data in the State of New South Wales

  2019cites this paper
• Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients

  2018cites this paper
• RESISTANCE TO DIRECTLY ACTING ANTIVIRALS FOR THE TREATMENT OF HCV A SUMMARY OF CURRENT KNOWLEDGE

  2017cites this paper
• Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents

  2017cites this paper
• Identificação de polimorfismos e mutações primárias de resistência aos inibidores de protease (NS3/NS4A) no vírus da hepatite C em pacientes com hepatite C crônica monoinfectados e coinfectados pelo vírus da imunodeficiência humana

  2017cites this paper
• Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment

  2017cites this paper
• Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co‐infected patients

  2017cites this paper
• Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.

  2017cites this paper
• Resistance-Associated Variants in HCV Subtypes 1a and 1b Detected by Ion Torrent Sequencing Platform

  2016cites this paper
• Viral dynamic modelling of Hepatitis C and resistance‐associated variants in haemophiliacs

  2016cites this paper
• Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance

  2016cites this paper
• Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening

  2016cites this paper
• Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.

  2016cites this paper
• Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis

  2016cites this paper
• Influence of host resistance on viral adaptation: hepatitis C virus as a case study

  2015cites this paper
• Influence of host resistance on viral adaptation : hepatitis C virus as a case study

  2015cites this paper
• Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C

  2015cites this paper
• Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations.

  2015cites this paper
• HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b

  2015cites this paper
• Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance

  2015cites this paper
• Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

  2015cites this paper
• Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra-deep pyrosequencing

  2015cites this paper
• Ultra-deep sequencing reveals dynamics of drug Resistance-Associated variants in Hepatitis C viruses: Relevance to treatment outcome and resistance screening

  2015cites this paper
• Étude du génome complet du virus de l'hépatite C par séquençage de nouvelle génération : mise au point et applications

  2015cites this paper
• A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants.

  2015cites this paper